TRAWS PHARMA INC (TRAW) Stock Price, Quote, News and Overview
NASDAQ:TRAW - Nasdaq - US68232V8845 - Common Stock - Currency: USD
TRAW Quote, Performance and Key Statistics
1.55
+0.02 (+1.31%)
The current stock price of TRAW is 1.55 USD. In the past month the price decreased by -39.69%. In the past year, price increased by 149.72%.
TRAW Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 68.04 | 838.54B | ||
| JNJ | JOHNSON & JOHNSON | 15.38 | 372.51B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.94 | 275.58B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.12 | 221.49B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.69B | ||
| MRK | MERCK & CO. INC. | 10.62 | 208.21B | ||
| PFE | PFIZER INC | 7.37 | 129.99B | ||
| SNY | SANOFI-ADR | 13.38 | 128.08B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.53 | 97.47B | ||
| GSK | GSK PLC-SPON ADR | 8.6 | 75.84B | ||
| ZTS | ZOETIS INC | 25.92 | 68.46B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 47.30B |
Related stock screener links
About TRAW
Company Profile
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The firm is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
Company Info
TRAWS PHARMA INC
12 Penns Trail
Newtown PENNSYLVANIA US
Employees: 16
Company Website: https://www.onconova.com/
Investor Relations: https://investor.onconova.com/
Phone: 12677593680
TRAWS PHARMA INC / TRAW FAQ
What is the stock price of TRAWS PHARMA INC today?
The current stock price of TRAW is 1.55 USD. The price increased by 1.31% in the last trading session.
What is the ticker symbol for TRAWS PHARMA INC stock?
The exchange symbol of TRAWS PHARMA INC is TRAW and it is listed on the Nasdaq exchange.
On which exchange is TRAW stock listed?
TRAW stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TRAWS PHARMA INC stock?
7 analysts have analysed TRAW and the average price target is 153 USD. This implies a price increase of 9770.97% is expected in the next year compared to the current price of 1.55. Check the TRAWS PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TRAWS PHARMA INC worth?
TRAWS PHARMA INC (TRAW) has a market capitalization of 7.86M USD. This makes TRAW a Nano Cap stock.
How many employees does TRAWS PHARMA INC have?
TRAWS PHARMA INC (TRAW) currently has 16 employees.
What are the support and resistance levels for TRAWS PHARMA INC (TRAW) stock?
TRAWS PHARMA INC (TRAW) has a resistance level at 1.84. Check the full technical report for a detailed analysis of TRAW support and resistance levels.
Is TRAWS PHARMA INC (TRAW) expected to grow?
The Revenue of TRAWS PHARMA INC (TRAW) is expected to grow by 6.81% in the next year. Check the estimates tab for more information on the TRAW EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TRAWS PHARMA INC (TRAW) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TRAW, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TRAW, evaluating the profitability, health, valuation and growth aspects
- TRAWS PHARMA INC (TRAW) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TRAWS PHARMA INC (TRAW) Sales and EPS estimates to see what analysts future expectations are.
- TRAWS PHARMA INC (TRAW) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TRAWS PHARMA INC (TRAW) Insider and Institutional Ownership to learn about the owners and their transactions.
- TRAWS PHARMA INC (TRAW) Stock Chart to make your own analysis
- TRAWS PHARMA INC (TRAW) Latest news and press-releases to stay up to date.
Does TRAWS PHARMA INC (TRAW) stock pay dividends?
TRAW does not pay a dividend.
When does TRAWS PHARMA INC (TRAW) report earnings?
TRAWS PHARMA INC (TRAW) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of TRAWS PHARMA INC (TRAW)?
TRAWS PHARMA INC (TRAW) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.9).
What is the Short Interest ratio of TRAWS PHARMA INC (TRAW) stock?
The outstanding short interest for TRAWS PHARMA INC (TRAW) is 1.93% of its float. Check the ownership tab for more information on the TRAW short interest.
TRAW Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TRAW. When comparing the yearly performance of all stocks, TRAW is one of the better performing stocks in the market, outperforming 95.18% of all stocks.
TRAW Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TRAW. Both the profitability and financial health of TRAW have multiple concerns.
TRAW Financial Highlights
Over the last trailing twelve months TRAW reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 1.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -219.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TRAW Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TRAW. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -17393% and a revenue growth 6.81% for TRAW